U.S. Bispecific Antibody Market Expands Beyond Cancer Into New Therapies
U.S. Bispecific Antibody Market (By Therapeutic Area/Indication: Oncology, Immuno-inflammation/Autoimmunity, Infectious Diseases, Ophthalmology/Rare Diseases/Others; By Format/Architecture: Dual-variable/IgG-based bispecifics, T-cell Engagers, Bispecific Fc-fusion/Fc-silent multispecifics, Trispecific/multispecific/conjugated bispecifics, Bispecific fragments & alternative scaffolds; By Development Stage: Preclinical & Discovery, Phase I/I–II Trials, Late-Stage, Commercial/Launched Products; By End User/Payer Channel: Oncology hospitals/cancer centers, Specialty infusion clinics, Academic medical centers, Community oncology & outpatient practices) Country-level Analysis, Size, Trends, Leading Companies, Regional Outlook and Forecast 2026 to 2035.
Last Updated : 27 April 2026
Category: Biotechnology
Insight Code: 6406
Format: PDF / PPT / Excel